New pill tested to tame painful lupus skin rashes

NCT ID NCT04857034

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an oral medication called deucravacitinib is safe and effective at reducing skin inflammation in people with discoid or subacute cutaneous lupus. About 74 participants with moderate to severe skin symptoms that aren't well controlled by standard treatments will receive either the study drug or a placebo for 16 weeks. Researchers will measure changes in skin rash severity and monitor for side effects to see if this new treatment offers better control of the condition.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution

Guadalajara, Jalisco, 45030, Mexico
Local Institution - 0001

Kogarah, New South Wales, 2217, Australia
Local Institution - 0002

Camberwell, Victoria, 3124, Australia
Local Institution - 0003

Botany, New South Wales, 2019, Australia
Local Institution - 0005

Rzeszów, 35-055, Poland
Local Institution - 0006

Hamburg, 22391, Germany
Local Institution - 0007

Clayton, Victoria, 0, Australia
Local Institution - 0008

Lodz, Łódź Voivodeship, 94-046, Poland
Local Institution - 0009

Wroclaw, 50-566, Poland
Local Institution - 0010

Paris, 75970, France
Local Institution - 0013

San Miguel de Tucumán, Tucumán Province, 4000, Argentina
Local Institution - 0014

Erlangen, 91054, Germany
Local Institution - 0018

Capital Federal, Buenos Aires, 1023, Argentina
Local Institution - 0019

Buenos Aires, 1431, Argentina
Local Institution - 0021

Taichung, 404, Taiwan
Local Institution - 0022

Taipei, 10051, Taiwan
Local Institution - 0023

Taichung, 402, Taiwan
Local Institution - 0026

Oklahoma City, Oklahoma, 73104, United States
Local Institution - 0027

Créteil, 94000, France
Local Institution - 0028

Guadalajara, 0, Mexico
Local Institution - 0029

Aguascalientes, 20130, Mexico
Local Institution - 0031

Kaohsiung City, 833, Taiwan
Local Institution - 0035

Berlin, 10117, Germany
Local Institution - 0036

Monterrey, Nuevo León, 64718, Mexico
Local Institution - 0037

New York, New York, 10029, United States
Local Institution - 0038

Bordeaux, 33075, France
Local Institution - 0046

Los Angeles, California, 90045, United States
Local Institution - 0054

Charleston, South Carolina, 29407, United States
Local Institution - 0058

Zapopan, Jalisco, 45070, Mexico
Local Institution - 0059

St Louis, Missouri, 63108, United States
Local Institution - 0060

Ann Arbor, Michigan, 48109, United States
Local Institution - 0065

Durham, North Carolina, 27713, United States
Local Institution - 0067

Columbus, Ohio, 43215, United States
Local Institution - 0071

Mexico City, 14080, Mexico
Local Institution - 0072

Dresden, Saxony, 01307, Germany
Local Institution - 0073

Farmington, Connecticut, 06030, United States
Local Institution - 0076

Irvine, California, 92697, United States
Local Institution - 0077

Scottsdale, Arizona, 85259, United States
Local Institution - 0078

Melbourne, Victoria, 3004, Australia
Local Institution - 0082

Orlando, Florida, 32827, United States
Local Institution - 0087

Victoria Park, Western Australia, 6100, Australia

Conditions

Explore the condition pages connected to this study.

LUPUS ERYTHEMATOSUS, DISCOID LUPUS ERYTHEMATOSUS, SUBACUTE CUTANEOUS